ScoreWhy is Ajanta Pharma Ltd. ?
1
High Management Efficiency with a high ROE of 21.01%
2
The company is Net-Debt Free
3
Poor long term growth as Operating profit has grown by an annual rate 8.86% of over the last 5 years
4
Flat results in Mar 26
- DEBTORS TURNOVER RATIO(HY) Lowest at 2.94 times
5
With ROE of 23.3, it has a Expensive valuation with a 8.5 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 23.79%, its profits have risen by 14.7% ; the PEG ratio of the company is 2.5
6
High Institutional Holdings at 26.64%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
7
Market Beating performance in long term as well as near term
- Along with generating 23.79% returns in the last 1 year, the stock has outperformed BSE500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Ajanta Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Ajanta Pharma for you?
Medium Risk, High Return
Absolute
Risk Adjusted
Volatility
Ajanta Pharma
23.79%
0.94
25.23%
Sensex
-3.33%
-0.25
13.43%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
13.07%
EBIT Growth (5y)
8.86%
EBIT to Interest (avg)
90.72
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.16
Sales to Capital Employed (avg)
1.10
Tax Ratio
23.35%
Dividend Payout Ratio
78.95%
Pledged Shares
17.94%
Institutional Holding
26.64%
ROCE (avg)
29.63%
ROE (avg)
21.01%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
36
Industry P/E
34
Price to Book Value
8.49
EV to EBIT
31.12
EV to EBITDA
27.25
EV to Capital Employed
9.22
EV to Sales
6.97
PEG Ratio
2.47
Dividend Yield
0.91%
ROCE (Latest)
29.63%
ROE (Latest)
23.33%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Sideways
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend5What is working for the Company
NET SALES(Q)
Highest at Rs 1,421.64 cr
-1What is not working for the Company
DEBTORS TURNOVER RATIO(HY)
Lowest at 2.94 times
Loading Valuation Snapshot...
Here's what is working for Ajanta Pharma
Net Sales - Quarterly
Highest at Rs 1,421.64 cr and Grown
each quarter in the last five quartersMOJO Watch
Near term sales trend is very positive
Net Sales (Rs Cr)
Net Sales - Quarterly
At Rs 1,421.64 cr has Grown at 21.47%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Here's what is not working for Ajanta Pharma
Debtors Turnover Ratio- Half Yearly
Lowest at 2.94 times
in the last five half yearly periodsMOJO Watch
Company's pace of settling its Debtors has slowed
Debtors Turnover Ratio
Non Operating Income - Quarterly
Highest at Rs 61.43 cr
in the last five quartersMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating Income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
